Metabolic Complications in Polycystic Ovary Syndrome
Main Article Content
Abstract
Polycystic ovarian syndrome (PCOS) is the most frequent endocrinopathy in women of childbearing age with a prevalence of approximately 9 to 18%, being more frequent in overweight women. It is a pathology that is manifested by irregular cycles and/or amenorrhea. At the same time, this pathology, also called Chronic Hyperandrogenic Anovulation, is usually accompanied by manifestations such as acne, hirsutism, and insulin resistance that can lead to diabetes, arterial hypertension, and alterations in the lipid profile in the long term.
Therefore, a Descriptive-Retrospective study of patients who presented metabolic complications due to Polycystic Ovarian Syndrome was carried out.
By knowing the clinical manifestations and pathophysiology of the disease, pharmacological treatment can be applied early, which will promote a healthy lifestyle in women with PCOS in order to limit and prevent the aforementioned subsequent metabolic complications.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Williams, J., Hoffman, B., & Pérez Tamayo Ruiz, A. (2014). Williams ginecología (4th ed. p 460-480). México, D.F.: McGraw-Hill Interamericana.
II. Jameson, L., Kasper, D., & Fauci, A. (2018). Harrison Principios de medicina interna (20th ed., p. cap. 386). México D. F.: McGraw-Hill.
III. Rosen M.P., & Cedars M.I. (2019). Endocrinología del sistema reproductor femenino e infertilidad. Gardner D.G., & Shoback D(Eds.), Greenspan. Endocrinología básica y clínica 10e. McGraw-Hill. https://accessmedicina.mhmedical.com/content.aspx?bookid=2745§ionid=232231550
IV. Miguel A. Sánchez-Garrido & Manuel Tena-Sempere. (February 5, 2020). Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. MOLECULAR METABOLISM, 35,
www.molecularmetabolism.com
V. Shiquin Zhu, Bingqian Shang & Xiao Jiang. (January 1, 2019). Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta.analysis. Fertility and Sterility, 111, 169-177
VI. Wu, C, Chui, L & Lee, M. (2020). Hypertension Risk in Young Women With Polycystic Ovary Syndrome: A Nationwide Population-Based Cohort Study. Octubre 26, 2020, de Frontiers in Medicine Sitio web:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538684/
VII. Delitala, A, Capobianco, G, Delitala, G, Cherchi, P & Dessole, S. (2017). Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Octubre 26, 2020, de CrossMark Sitio web:
https://link.springer.com/article/10.1007/s00404-017-4429-2
VIII. Gunning, N & Fauser, M. (2017). Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life?. Octubre 27, 2020, de Crossmmark Sitio web:
https://doi.org/10.1080/13697137.2017.1316256
IX. Dongargaonkar, P., Aher S. & Gavali U.(2020). Non obese and Obese Women with Polycystic Ovary Syndrome- Their Metabolic Characteristics and Insulin Resistance. February 18, of Scholars International Journal of Obstetrics and Gynecology.
X. Kempegowda, P., Melson, E., Manolopoulos, K. (2020) Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. March 9 Therapeutic Advances in Endocrinology and Metabolism
XI. Benson, B., Severn, C., & Hudnut-Beumler, J. (2020). Depression in girls with obesity and polycystic ovary syndrome and/or type 2 diabetes. May 26, of Canadian Journal of diabetes.
XII. 12. Katica Bajuk Studenm & Marija Pfeifer. (Mayo 14, 2018). Cardiometabolic risk in polycystic ovary syndrome. Endocrine Connections http://www.endocrineconnections.org https://doi.org/10.1530/EC-18-0129
XIII. Emily W. Gilbert, Chau T. Tay, Danielle S. Hiam, Helena J. Teede. (2018). Comorbidities and complications of polycystic ovary syndrome. An overwiew of systematic reviews. July 6, 2018.